Showing posts with label liver cancer. Show all posts
Showing posts with label liver cancer. Show all posts

Wednesday, December 9, 2015

Renal cell carcinoma

Patients with metastatic renal cell carcinoma (RCC) to the brain have a very poor prognosis of three months if left untreated. SRS is an effective treatment modality in numerous patients. This case exemplifies the utility of stereotactic radiosurgery (SRS) in prolonging survival and maintaining quality of life in a patient with RCC. This 64-year-old female patient initially presented to her primary care physician 22 months after a left nephrectomy for RCC with complaints of mild, intermittent headaches and difficulty with balance. An MRI revealed five cerebellar lesions suspicious for intracranial metastasis. The patient's first GKRS treatment targeted four lesions with 22 Gy at the 50% isodose line. She underwent a total of seven GKRS treatments over the next 60 months for recurrent metastases to the brain. 72 months and 12 months have now passed since her brain metastases were first discovered and since her last GKRS treatment, respectively, and this woman is alive with considerable quality of life and no evidence of metastatic reoccurrence. This case shows that repeated GKRS treatments, with minimal surgical intervention, can effectively treat multiple intracranial lesions in select patients, prolonging survival and avoiding iatrogenic neurocognitive decline while maintaining a high quality of life.

To know more about cyberknife kindly blog your comments or you can write to me at lakshmipriya_b@apollohospitals.com or call 9940675877

Monday, July 12, 2010

Cholangiocarcinoma treated with CyberKnife

Cholangiocarcinoma treated with CyberKnife

Introduction: Cholangiocarcinoma is a relatively rare disease, however has poor prognosis. Liver resection or transplantation is only curative treatment (1). Unfortunately, majority of the patients present with locally advanced, unresectable disease with extensive tumor spread (2). The treatment is not yet standardized. They are treated with either chemotherapy or radiotherapy or in combination (2-6). CyberKnife is recent advancement in radiation therapy delivery system which has high accuracy and flexibility in targeting the tumor through image-guided stereotactic body radiotherapy (SBRT) system (7).

Case history: Forty eight year old gentleman from Uttar Pradesh, India was diagnosed with inoperable cholangiocarcinoma eight months back. He was treated with chemotherapy for four months. However, post-chemotherapy imaging evaluation did not show any significant response. He was diagnosed as chemo-resistant inoperable cholangiocarcinoma. His liver function was maintained and general condition was good. As he was suffering from inoperable, chemotherapy resistant cholangiocarcinoma, he was referred for radiation therapy and was evaluated for robotic radiosurgery (CyberKnife) treatment. After appropriate evaluation, imaging (PET scan), fiducial placement and planning he was treated with CyberKnife. He received 30 Gy in 5 fractions in one week. Dose to the target was adequate and to adjacent normal structures were within normal limits. He completed treatment without any severe toxicity and is on regular follow up.

Discussion: In early operable choloangiocarcinoma, 3-year overall survival rate after curative surgery is only 40-60% (1-2). Advanced unresectable cholangiocarcinoma patients have poorer prognosis as well as severe complications due to biliary stasis (3,4). They are mainly treated with supportive or palliative care. Main aims of treatment in these patients are to preserve quality of life and improve survival rate. Palliative therapy options in these patients are chemotherapy, radiotherapy, photodynamic therapy and biliary drainage procedures (5). Median survival with palliative chemotherapy and external beam radiation therapy are 5 to 9 and 9 to 12 months respectively (2-6). Inoperable, advanced cholangiocarcinomas remain localized and distant metastasis is not common (1). Hence, these tumours may be treated with localized treatment options with maximum effect. However, cholangiocarcinomas are relatively resistant to both radiation and chemotherapy. Hence, high dose radiation therapy is required to have desired loco-regional control (7). CyberKnife radiosurgery is a SBRT using real time respiratory-motion tracking system, and is known to exert minimal normal tissue injury. High dose of radiation treatment in few fractions are possible with CyberKnife which increases tumour control probability without increasing toxicity (7). High dose radiation therapy with proton beam therapy also has shown promising loco-regional control without additional severe toxicity (2). We suggest that CyberKnife might be a safe and useful treatment option in advanced, unresectible cholangiocarcinoma.

For more information you may please blog your comments or write to lakshmipriya_b@apollohospitals.com

Tuesday, January 5, 2010

CYBERKNIFE FOR GASTRIC CANCERS

Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer

Metastases from gastric cancer are common and can progress rapidly; even with aggressive treatment 5-year survival rates are low. However, researchers from Korea Institute of Radiological & Medical Sciences hypothesized that there is a certain population of such patients in whom the disease follows a more indolent course, based on studies of patients with
resected liver metastases. This population may benefit from SRS of isolated metastases from
gastric primaries. Thus, they treated 7 such patients with the CyberKnife® System, delivering 45 to 51 Gy (median 48 Gy) in 3 fractions. The patients were followed for 14 to 33 months (median 26 months). Local control was achieved in 6 of 7 patients; 2 patients were disease-free, 3 were alive with disease, and 2 patients died of disease progression. Three-year actuarial overall survival was 43%, and disease-free survival was 29%. The authors conclude that the results support their hypothesis that an indolent subgroup with less aggressive disease progression who could benefit
from the use of local treatments such as CyberKnife Radiosurgery.
 
Source: Accuray's focus newsletter